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ABSTRACT* 
Objective: To compare antihyperglycemic 
medication adherence and glycemic control 
between individuals with schizophrenia and related 
psychotic disorders and a nonpsychiatric 
comparison group.  
Methods: This was a retrospective medical record 
review. A total of 124 subjects with diabetes (62 
patients with schizophrenia or a related psychotic 
disorder and 62 randomly selected, age-matched 
patients without a psychiatric illness) receiving their 
medical and psychiatric care exclusively through the 
Kansas City Veterans Affairs healthcare system 
during 2008 were included in the study. Adherence 
to antihyperglycemic and antipsychotic medication 
was determined by refill records obtained through 
the computerized patient record system to calculate 
the cumulative mean gap ratio. Hemoglobin A1C 
values were utilized to compare glycemic control 
between groups and compared to glycemic goals 
established by diabetes treatment guidelines.  
Results: Antihyperglycemic medication adherence 
was poor for both groups as approximately 60% of 
the psychotic disorder group and 75% of the 
nonpsychiatric comparison group were without 
antihyperglycemic medication for greater than 30 
days during the 12-month period but adherence did 
not differ between the groups (p=0.182). 
Antipsychotic adherent subjects (≥80% adherent) 
were more likely to be adherent to their 
antihyperglycemic medication (p=0.0003). There 
were no significant differences between groups in 
glycemic control.  
Conclusion: Antihyperglycemic medication 
adherence and glycemic control was less than 
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optimal for both groups. There were no significant 
differences in antihyperglycemic medication 
adherence and glycemic control between patients 
with a psychotic disorder and those without a 
psychiatric illness.  
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CUMPLIMIENTO DE LA MEDICACIÓN Y 
CONTROL GLUCÉMICO EN PACIENTES 
CON DESORDENES PSICÓTICOS EN EL 




Objetivo: Comparar la adherencia a la medicación 
antihiperglucémica y el control glucémico entre 
individuos con esquizofrenia y desordenes 
psicóticos relacionados y un grupo de comparación 
no psiquiátrico. 
Métodos: Esto fue una revisión retrospectiva de 
historiales clínicos. Se incluyeron en el estudio a un 
total de 124 individuos con diabetes (62 pacientes 
con esquizofrenia o desordenes psicóticos 
relacionados y 62 pacientes sin enfermedad 
psiquiátrica aleatoriamente seleccionados y 
emparejados por edades) que recibían su 
medicación y sus cuidados psiquiátricos 
exclusivamente a través del sistema sanitario de la 
Oficina de Veteranos de Kansas City durante 2008. 
La adherencia a la medicación antihiperglicemica y 
antipsicótica se determinó de los registros de 
recogida de medicación a través del sistema 
informático para calcular el porcentaje de 
discordancia medio acumulativo. Se utilizaron los 
valores de hemoglobina A1C  para comparar el 
control glucémico entre los grupos y comparar con 
los objetivos glucémicos establecidos en las guias 
de tratamiento. 
Resultados: La adherencia a la medicación 
antihiperglucémica fue pobre en ambos grupos, ya 
que aproximadamente el 60% del grupo de 
desordenes psicóticos y el 75% del grupo de 
comparación no psiquiátrico estuvieron sin 
medicación antihiperglucémica durante más de 30 
días en el periodo de 12 meses pero la adherencia 
no fue diferente entre los grupos (p=0,182). Los 
individuos adherentes a los antipsicóticos (≥80% 
adherentes) eran más adherentes a sus 
antihiperglucémicos (p=0,0003). No hubo 
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diferencias significativas entre los dos grupos en el 
control glucémico. 
Conclusión: La adherencia a la medicación 
antihiperglucémica y el control glucémico fue 
menos que óptimo en los dos grupos. No hubo 
diferencias significativas en la adherencia a la 
medicación antihiperglucémica y al control 
glucémico entre pacientes con un desorden 
psicótico y los que no tenían enfermedad 
psiquiátrica. 
 
Palabras clave: Adherencia a la medicación. 
Diabetes Mellitus. Desordenes Psicóticos. 





Nonadherence to antipsychotic therapy in patients 
with schizophrenia has been studied extensively as 
nonadherence can have significant and costly 
consequences including relapse of psychosis 
resulting in increased clinic or emergency room 
visits or hospitalization.1 A comprehensive review of 
the literature reports antipsychotic nonadherence to 
be 40-50%.2 Nonadherence is likely not to be 
limited to antipsychotic therapy in patients with 
psychotic illness. Examining medication adherence 
rates associated with the treatment of comorbid 
medical illnesses is important as these commonly 
occur in psychiatric patients, can be drug-induced, 
and have adverse long-term consequences if not 
adequately treated.3 Mortality in persons with 
schizophrenia is 2-4 times greater than the general 
population.4-6 Treatment with antipsychotic 
medications, especially second generation 
antipsychotics, is linked to increased rates of 
obesity, diabetes and dyslipidemia.3 Although some 
of the increased risk can be attributed to a higher 
rate of suicide, lack of appropriate care for chronic 
medical illnesses, which can include medication 
nonadherence, may also be a factor associated with 
increased mortality. Additionally, patients with 
schizophrenia can have significant cognitive deficits 
and lack of insight into their disease processes and 
the need for treatment which can also increase the 
risk for nonadherence and negative treatment 
outcomes further justifying the need for studies in 
this area.7 
Although adherence to medication regimens for 
medical disease states such as hypertension, 
diabetes, and hyperlipidemia has been studied in 
patients without psychiatric illnesses, few studies 
have been conducted in patients with comorbid 
psychiatric illnesses. Adherence to medication 
regimens for diabetes is less than optimal in 
patients without psychiatric illnesses ranging from 
36-93%.8 A published review of the literature from 
1975-1996 compared compliance rates with 
psychiatric medications with those of medication 
regimens for medical illnesses.9 Patients receiving 
antipsychotics took an average of 58% (range 24-
90%) of the recommend quantity of medications as 
compared to 65% (range 40-90%) in patients 
receiving an antidepressant and 76% (range 60-
92%) in patients with medical illnesses. This study 
suggests that medication adherence among 
patients with psychiatric illness may be lower than 
among patients with medical illnesses. This is an 
important study as it was the first to compare 
medication adherence rates between these 
populations but needs to be interpreted with caution 
as adherence rates were not assessed by the same 
measure in all cited studies.  
To date, only four studies have specifically 
evaluated adherence to medication regimens for 
medical illnesses in a psychiatric patient population 
and only one of these studies evaluated clinical 
outcomes.10-13 Dolder and colleagues evaluated 
adherence to nonpsychiatric medications for 
diabetes (n=24), hypertension (n=60) and 
hyperlipidemia (n=28) in a sample of middle-aged 
and older outpatients with schizophrenia or other 
psychotic disorders receiving care in a Veterans 
Affairs (VA) healthcare setting.10 Medication refill 
records were used to assess adherence to calculate 
compliant fill rate (the number of adherent fills in 
proportion to the total number of prescription fills) 
and cumulative mean gap ratio (CMGR) (the 
number of days when medication was unavailable in 
relation to the total number of days during the same 
time period).14-16 In other words, as the CMGR 
approaches zero, the more adherent a patient is 
with prescribed therapy. No significant differences 
were found between medication classes in terms of 
compliant fill rate or CMGR at 6 or 12 months 
(p=0.086; p=0.20 respectively). Twelve-month 
compliant fill rates ranged from 52-64%. Twelve-
month CMGR ranged from 5-15% which means that 
average gaps in therapy varied from 2-5 days per 
month. Overall rates of nonadherence were similar 
for all medication classes. This study concluded that 
nonadherence rates were suboptimal for both 
antipsychotic and nonpsychiatric medications in this 
study population. The retrospective design and 
small sample size were limitations of this study. 
Peitte and colleagues evaluated medication 
adherence among veterans with schizophrenia and 
comorbid diabetes and hypertension (n=1,686).11 
Adherence was assessed for each medication type 
by calculating medication possession ratios (MPR) 
which measures the total number of days of 
medication supplied by the number of days needed. 
This study found only a moderate correlation 
between adherence to antipsychotic medication and 
adherence to drug therapy regimens for diabetes 
and hypertension. In a multivariate analyses 
adjusted for days’ supply of medication dispensed, 
the adjusted odds for nonadherence were 
significantly greater for antihyperglycemic (adjusted 
OR 1.5; p<0.001) and antihypertensive (adjusted 
OR 1.5; p<0.001) medications than antipsychotic 
medication.  
The most recently published study evaluated 
adherence to antihyperglycemic medication in 
patients with (n=11,454) and without (n=10,560) 
schizophrenia receiving care in the VA healthcare 
system.12 Nonadherence was defined as a MPR 
less than 0.8 reflecting less than 80% of medication 
needed for continuous treatment was taken. This 
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study found that the prevalence of medication 
adherence (MPR= 0.8-1.2) to antihyperglycemic 
medication was significantly higher (51% vs. 46%; 
p<0.0001) and the prevalence of antihyperglycemic 
medication nonadherence (MPR<0.8) was 
significantly lower (43% vs. 52%; p<0.0001) in 
diabetes patients with schizophrenia than without 
schizophrenia. This study is the largest to date 
comparing adherence to antihyperglycemic 
medication among diabetes patients with and 
without schizophrenia.  
Dolder and colleagues compared antihypertensive 
medication adherence and blood pressure control 
among middle-aged and older outpatients with 
schizophrenia or other psychotic disorders (n=89) 
as compared to age-matched patients without a 
psychiatric illness (n=89).13 Refill records were used 
to assess adherence using CMGR and electronic 
records were used to obtain blood pressure 
readings. There was no difference in the CMGR 
ratio between groups (p=0.71) with mean 
adherence rates reflecting approximately 40 days 
without antihypertensive treatment during the 1-year 
study. Despite similar adherence rates, attainment 
of blood pressure goal was achieved less often in 
the psychiatric group as compared to the 
nonpsychiatric group, which could be associated 
with a poorer outcome. Although the study utilized a 
retrospective design and had a limited sample size, 
this is the only study evaluating differences in a 
clinical outcome for a medical illness between 
patients with and without a comorbid psychotic 
illness. This study supports the need for further 
prospective evaluation of blood pressure control 
between these patient groups. Furthermore, with 
the conflicting adherence information coupled with 
the lack of clinical outcomes for other commonly 
encountered medical illnesses, such as diabetes 
and hyperlipidemia, pilot data is needed.  
The purpose of our study was to compare 
antihyperglycemic medication adherence and 
glycemic control between outpatients with 
schizophrenia and related psychotic disorders and 




The study was approved by the University of 
Missouri-Kansas City Adult Health Sciences 
Institutional Review Board and the Kansas City 
Veterans Affairs Medical Center (KCVAMC) Human 
Studies and Research and Development 
Committees. The Veterans Health Administration is 
the United States largest integrated health care 
system. Approximately 150 medical centers and 
community-based outpatient clinics provide primary 
and specialty care for more than five million 
veterans annually. The KCVAMC currently provides 
services to over 43,000 veteran patients. Hospital-
based services of the KCVAMC include, but are not 
limited to, acute care medicine, surgical and mental 
health care. In addition, this medical center offers 
additional medical and surgical specialty services 
including geriatric, neurology, cardiology, 
pulmonary, psychiatry, gastrointestinal and 
oncology medicine. Subjects were drawn from 
individuals identified as being prescribed an oral 
agent for the treatment of diabetes and 
hyperlipidemia during 2008 using the KCVAMC 
computer database. From this criteria, we then 
selected for inclusions those who: 1) had a 
minimum of two oral antihyperglycemic and 
antihyperlipidemic prescriptions (i.e. at least 60 
days’ worth of medication) filled during the 12-
month study period and; 2) were receiving their 
general medical care including treatment for 
diabetes and hyperlipidemia exclusively at the 
KCVAMC Primary Care Clinics providing a sample 
of 9,606. Patients with Type I Diabetes receiving 
insulin were not included in the study. Of these 
subjects, two study groups were formed based on 
1) those with a psychotic disorder and 2) those 
without a diagnosis of psychiatric illness. To identify 
the psychotic disorder group, subjects receiving a 
prescription for any oral antipsychotic medication 
during the same timeframe were identified from the 
previous sample. Of 248 subjects, we selected for 
inclusion those who: 1) had a minimum of two oral 
antipsychotic prescriptions filled (i.e. at least 60 
days’ worth of medication) during the 12-month 
study period and; 2) were receiving their psychiatric 
care exclusively at the KCVAMC. Patients whose 
primary treatment for psychosis was a long-acting 
injectable antipsychotic were excluded. The 
computerized patient record system (CPRS) was 
utilized to confirm ICD-9 diagnostic codes for 
diabetes (ICD-9 code 250), hyperlipidemia (ICD-9 
code 272) in both groups along with schizophrenia, 
schizoaffective disorder or psychosis not otherwise 
specified (ICD-9 codes 295.1, 295.2, 295.3, 295.4, 
295.6, 295.7, 295.9, 298.9) for the psychotic group. 
Additionally, this process was used to verify lack of 
a psychiatric illness in the nonpsychiatric 
comparison group. 
Sixty-two subjects with a psychotic illness were 
identified as meeting all inclusion criteria including 
receiving medications for a psychotic illness, 
diabetes and hyperlipidemia. All were included in 
the study. An equal number of age-matched 
individuals (within 4 years) without a psychiatric 
illness were randomly selected from the original 
pool. 
Subjects receiving the following classes of 
antihyperglycemic medications were included in the 
study: biguanides (metformin), sulfonylureas 
(glyburide, glipizide), and/or thiazolidinediones 
(rosiglitazone, pioglitazone). These medication 
classes are the most commonly prescribed oral 
agents to treat diabetes at the KCVAMC and 
metformin is considered first line pharmacotherapy 
for the treatment of diabetes based on treatment 
guidelines.17 All three antihyperglycemic medication 
classes were used to identify the original study 
sample. Subjects receiving HMG-CoA reductase 
inhibitors, commonly referred to as statins, were 
included in the study as they are the most 
commonly prescribed class of antihyperlipidemic 
medications at the KCVAMC and represent first line 
pharmacotherapy for hyperlipidemia based on 
treatment guidelines.18 Use of a HMG-CoA 
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reductase inhibitor was used to identify the original 
study sample.  
If the subject was receiving combination therapy for 
the treatment of hyperlipidemia, data were also 
collected for the following antihyperlipidemic 
medications: fibrates, niacin, bile acid resins and 
ezetimibe. Subjects receiving a first generation 
antipsychotic (FGA) and/or second generation 
antipsychotic (SGA) in an oral formulation were 
included in the study. Medications in both classes of 
antipsychotics were used to identify the original 
study sample as both classes have utility in the 
treatment of schizophrenia.19 
Data was collected from subjects having both 
diabetes and hyperlipidemia to compare two 
samples with an additional diabetes disease state 
management indicator and to reduce a potential 
confounder of less aggressive care in either group. 
We will only report outcomes associated with 
diabetes in this manuscript.  
Data Collection 
Electronic medical record review from the CPRS 
during 2008 was used to collect demographic and 
clinical information including age, gender, ethnicity, 
body mass index (BMI)20, psychiatric and 
nonpsychiatric diagnoses21,22, duration of illness, 
smoking status, institutional encounters occurring in 
2008 (i.e. primary care clinic visits, nonpsychiatric 
and psychiatric emergency room visits and 
hospitalizations), and medication history. All 
laboratory assessments for hemoglobin A1C (A1C) 
documented in 2008 were also collected.  
Adherence to antihyperglycemic and antipsychotic 
medication was determined by refill records 
obtained through the CPRS in 2008. For each 
subject, rates of adherence were determined for 
both classes of medication and for each medication 
within a class if the subject was using combination 
therapy for the treatment of diabetes and/or 
psychosis. If a subject was taking more than one 
medication for diabetes or psychosis, the 
medication with the greatest nonadherence was 
selected for the adherence assessment.  
Medication adherence was assessed by calculating 
the CMGR.14-16 CMGR is calculated by dividing the 
number of days of medication that were unavailable 
for consumption (due to delayed refills) by the total 
number of days during the same time period. 
CMGR ratios provide a continuous assessment of 
gaps in therapy for each subject’s 
antihyperglycemic and antipsychotic medication. 
This method of assessing adherence has been 
used in previous studies evaluating antipsychotic 
and nonpsychiatric medication adherence.10,11,13,23  
In addition to calculating antihyperglycemic 
medication adherence rates, A1C values were 
utilized to compare glycemic control between 
groups. These values were evaluated in relation to 
the glycemic goals established by the Standards of 
Medical Care in Diabetes-2008.17 Adequate 
glycemic control was determined by comparing 
each subject’s A1C with the treatment goals set by 
these guidelines. The percentage of A1C 
measurements that met the target goal was 
calculated for each subject and the mean 
percentage of measurements that met goal was 
then compared between the groups.  
Statistical Analysis  
Descriptive statistical analysis for all study variables 
were defined by mean, standard deviation, and 
interquartile range (IQR) for continuous variables. 
Frequency and percentages for categorical 
variables were reported. Demographic and 
outcomes variables were assessed for statistical 
significance between treatment groups using 
bivariate analysis (e.g. Pearson’s chi square test, F 
test, t-test). Statistical software Stata 9 was used for 




Patient and Treatment Characteristics 
A comparison of baseline demographic data and 
clinical characteristics for the psychosis and 
nonpsychiatric comparison groups is found in Table 
1. Overall, both groups were composed mostly of 
males, who were obese and had hyperlipidemia and 
at least two additional medical disorders other than 
diabetes. No significant differences between the 
age-matched groups were found for BMI, duration 
of diabetes, medical comorbidities, or healthcare 
utilization (primary care visits and hospitalizations) 
for medical needs. There was a significant 
difference between the groups with regard to race 
with fewer whites and more blacks composing the 
psychosis group as compared to the nonpsychiatric 
group. The percentage of smokers in the psychosis 
group was higher (37.1% vs. 14.5%; p=0.004). 
Additionally, subjects in the psychosis group had 
more emergency room visits for a medical reason 
than the nonpsychiatric comparison group 
(p=0.001).  
The majority of the subjects in the psychosis group 
were diagnosed with schizophrenia (67.7%). Most 
were prescribed a SGA (n=53; 85%) with 
risperidone being the most common (n=17; 27.4%) 
followed by ziprasidone (n=10; 18.9%). Other SGA 
prescribed to subjects included olanzapine, 
quetiapine and aripiprazole. Eighteen subjects 
(29.0%) were prescribed a FGA with 7 of these 
subjects (38.9%) receiving it in combination with a 
SGA. With respect to antihyperglycemic 
medications, individuals were prescribed similar 
agents. No significant differences existed between 
groups in the medication classes (biguanides, 
sulfonylureas, thiazolidinediones) prescribed in 
terms of the use of monotherapy vs. combination 
therapy (see Table 1). Additionally, there were no 
significant differences for the antihyperglycemic 
agent used in the assessment of adherence for 
individual subjects (see Table 1). 
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Table 1.  Baseline Demographic Data and Clinical Characteristics of Psychosis and Nonpsychiatric Comparison Subjects 
Parameter 
Subjects without a 




Age (years), mean (SD) 59.3 (2.2) 57.9 (7.0) 0.155 





















Body Mass Index (kg/m2), mean ± SD 34.5 ± 7.4 33.5 ± 6.3 0.447 
Body Mass Index Classification20, N (%) 
Underweight (BMI <18.5 kg/m2) 
Normal weight (BMI 18.5-24.9 kg/m2) 
Overweight (BMI 25-29.9 kg/m2) 
Obesity Class I (BMI 30-34.9 kg/m2) 
Obesity Class II (BMI 35-39.9 kg/m2) 
















Duration of Diabetes (years), mean (SD) 5.3 (3.1) 6.5 (5.4) 0.081 
Psychiatric Disorder, N (%) 
     Schizophrenia 
     Schizoaffective Disorder 








Comorbid Medical Diagnoses, N (%) 
Hyperlipidemia 
Hypertension 
Coronary Artery Disease (CAD) or Other CAD 
Risk Equivalent*      
Total Comorbid Medical Diagnoses**, N (%) 
     1  
     2 
     3 



























Smoking, N (%) 9 (14.5) 23 (37.1) 0.004 
Health Care Utilization, mean (SD) 
     Primary Care Visits 
     Medical Emergency Room Visits   
     Psychiatric Emergency Room Visits 
     Medical Hospitalizations 



















Antihyperglycemic Medication Classes Prescribed, N (%) 
     1 Medication Class/Drug 









Antihyperglycemic Medication Used for Adherence 
Calculation, N (%) 
     Metformin 
     Sulfonylurea 













*Other Coronary Artery Disease (CAD) Risk Equivalent = Cerebrovascular Disease, Peripheral Artery Disease, Abdominal Aortic 
Aneurysm 
** Total Comorbid Diagnoses included the following disease states found in the chronic disease score instrument which uses 
pharmacy data to measure an individual’s comorbidity (CAD, peripheral artery disease, abdominal aortic aneurysm, smoking,  
hypertension, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, cancer, Parkinson’s disease, seizure disorder, 
peptic ulcer disease, glaucoma and migraine headaches).21,22  Hyperlipidemia was also included in the number of total comorbid 
diagnoses. 
*** comparison made between metformin vs. all other antihyperglycemic drugs (sulfonylurea or thiazolidinedione) 
 
Table 2.  Glycemic Control in Psychosis and Nonpsychiatric Comparison Subjects 
Parameter 
Subjects without a 
psychiatric Illness (N=62) 
Subjects with psychosis 
(N=62) 
P-value 
Hemoglobin A1C - baseline, % mean (SD) 6.9 (1.7) 7.0 (1.4) 0.679 
Hemoglobin A1C - final, % mean (SD) 7.1 (1.6) 7.0 (1.6) 0.790 
Hemoglobin A1C – change from baseline to endpoint, % 
mean (SD) 
0.2 (2.0) 0.1 (1.2) 0.582 
Hemoglobin A1C <7% - final, N (%) 42 (68.2) 38 (61.3) 0.370 
Hemoglobin A1C at goal, N (%)17 
100% of assessments 
75-99% of assessments 
50-74% of assessments 
25-49% of assessments 
1-24% of assessments 
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Adherence  
Metformin was used to calculate the cumulative 
mean gap ratio in 58.9% of the subjects, 
sulfonylureas in 35.5% and thiazolidinediones for 
the remainder. No significant difference in the 
CMGR for antihyperglycemic medications was 
found between the psychosis (mean=15.8%, 
SD=16.8) and nonpsychiatric (mean=19.7%, 
SD=15.6) comparison groups (p=0.182). The mean 
adherence rates reflected approximately 58 days 
without medication in the psychosis group and 72 
days in the nonpsychiatric comparison group during 
the 12-month period. Figure 1 depicts the months 
per year antihyperglycemic medication was not 
consumed based on refill data for both groups. For 
each subject’s antihyperglycemic adherence 
calculation, the total number of days of therapy 
assessed during 2008 was tabulated. No difference 
between the two groups was found for metformin 
(p=0.186) with a mean duration of assessment for 
the overall sample of 279 days (SD=113) or 
sulfonlyureas (p=0.684) with a mean duration of 



























Figure 1.  Antihyperglycemic Medication Adherence 
Psychosis and Nonpsychiatric Comparison Subjects 
The antipsychotic CMGR for subjects in the 
psychosis group was 18.3% (SD=16.4) indicating 
approximately 68 days without medication during 
the 12-month period. Figure 2 depicts the months 
per year antipsychotic medication was not 
consumed based on refill data. The mean duration 
of assessment for the SGA for which the majority of 
the psychosis group was receiving was 262 days 
(SD=104). For the psychosis group, there was a 
significant correlation between antipsychotic and 
antihyperglycemic medication adherence. If the 
subject was ≥80% adherent to their antipsychotic 
therapy, they were more likely to be adherent to 
their antihyperglycemic therapy (p=0.0003). 
Antipsychotic adherent subjects had an 
antihyperglycemic CMGR of 10.7% (SD=10.2) 
indicating approximately 39 days without 
antihyperglycemic medication during a 12-month 
period. Antipsychotic nonadherent subjects, defined 
as an adherence rate <80%, had an 
antihyperglycemic CMGR of 26.6% (SD=22.3) 
indicating approximately 97 days without drug 
therapy for their diabetes. 
Glycemic Control 
A1C taken in primary care outpatient clinics were 
evaluated to assess glycemic control by using 
established diabetes treatment goals.17 There were 
no significant differences between groups in 
glycemic control (see Table 2). Fifty-three percent of 
the psychosis subjects were at goal for A1C on all 
glycemic assessments during 2008 while 51.6% of 
the nonpsychiatric comparison group met this 
outcome. Twenty-seven percent of the subjects in 
the psychosis group did not obtain an A1C goal of 
<7% at any time during the study period as 
































Our study is the first to date to compare both 
glycemic control and medication adherence rates 
for oral antihyperglycemic agents in patients with 
psychosis compared to patients without psychiatric 
illness. Our study found no difference in 
antihyperglycemic medication adherence between 
groups. The only other published study comparing 
antihyperglycemic medication adherence between 
these two patient populations found that the 
prevalence of antihyperglycemic medication 
adherence was significantly greater (MPR=0.8-1.2) 
and antihyperglycemic medication nonadherence 
(MPR<0.8) was significantly lower in diabetes 
patients with schizophrenia than without 
schizophrenia.12 Our study did find a relationship 
between adherence rates for antipsychotic and 
antihyperglycemic medication. If a patient took at 
least 80% of the prescribed antipsychotic, they were 
significantly more likely to be adherent to their drug 
therapy for diabetes. 
We did not find any published studies that 
specifically compared antihyperglycemic medication 
adherence rates and clinical outcome (i.e. glycemic 
control) between patients with psychosis and a 
nonpsychiatric control group. The study by Dolder 
and colleagues is the only study of this kind but 
evaluated blood pressure control.13 This study 
reported differences in blood pressure control 
between groups with the psychosis group having 
significantly less blood pressure control than an 
age-matched nonpsychiatric comparison group 
although there was no difference in antihypertensive 
medication adherence between groups. Our study 
found no significant difference between groups for 
glycemic control with both baseline and final A1C 
values being nearly identical between groups. 
The finding of no significant differences between 
groups for antihyperglycemic medication adherence 
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and glycemic control is surprising as several studies 
have found depression to be associated with a 
higher likelihood of antihyperglycemic medication 
nonadherence and poor diabetes control.24-26 
Schizophrenia is one of the most disabling 
psychiatric illnesses and can be associated with a 
lack of insight and judgment and, similar to 
depression, has cognitive deficits associated with 
the disease. Thus one would expect psychiatric 
illness in general and, specifically schizophrenia, to 
negatively impact adherence and clinical outcomes 
for medical illnesses. Additionally, previous 
literature has reported disparities in the quality of 
diabetes care received by patients with a psychiatric 
illness compared to patients without a psychiatric 
illness.27  
Our study supports a growing body of literature that 
suggests the quality of care for adequate diabetes 
control is not compromised for those patients with 
diabetes and psychiatric illness as compared with 
those without psychiatric illness who are receiving 
ongoing care.28-33 Two of these studies were 
conducted in the VA healthcare setting which is 
directly applicable to our study population.28,31 
Despite our finding that there was no significant 
difference in antihyperglycemic medication 
adherence between groups, the overall rate of 
medication adherence for both groups was less 
than optimal as approximately 60% of the psychosis 
group and 75% of the nonpsychiatric comparison 
group were without antihyperglycemic medication 
for greater than 30 days during the 12-month 
period. Additionally, approximately 18% of the 
psychosis group and 27% of the nonpsychiatric 
comparison group did not achieve goal for A1C at 
any assessment: 19% and 10%, respectively, had 
A1C values over 9%. Irregardless of this lack of 
goal attainment, our study demonstrated fewer 
patients with poor glycemic control, defined as A1C 
over 9% by the National Committee on Quality 
Assurance, compared with other insured 
populations in the commercial (28.4%), Medicare 
(29.4%) or Medicaid (44.8%) systems during 
2008.34 
Medication adherence may have been enhanced 
due to increased healthcare utilization in the 
psychotic disorder group. These subjects had 
significantly more visits to the emergency room for 
medical reasons than the nonpsychiatric 
comparison group (p=0.001). Additionally, there 
was also a trend for more medical hospitalizations 
in the psychotic disorder group (p=0.073). Due to 
their psychiatric illness, subjects in the psychotic 
disorder group had additional healthcare 
interactions. In addition to psychiatric emergency 
room visits and psychiatric hospitalizations, typically 
patients with schizophrenia and other related 
psychotic disorders require outpatient services 
through Behavioral Health. Therefore, subjects in 
the psychotic disorder group most likely received 
care or services offered beyond that given to the 
subjects without a psychiatric illness. These 
healthcare system interactions could have provided 
an opportunity to improve medication adherence.  
The findings of our study must be interpreted with 
consideration to the retrospective design and small 
sample size, which likely impacted our results. We 
had strict inclusion criteria which resulted in only 62 
subjects for the psychotic group in the specified 
timeframe. In addition to the small sample size, 
other study limitations exist. Our study focused 
specifically on a sample within the VA healthcare 
system which represented a primarily older, male 
subset thus our results may not generalize to other 
segments of the US population. We had strict 
inclusion criteria with the intent to make the 
psychosis and nonpsychiatric comparison group 
comparable on demographic and treatment-related 
variables which further narrowly defined our study 
population. The VA healthcare system places a 
significant amount of emphasis on the quality of 
processes and outcomes of diabetes care which 
may differentiate the diabetes care received in this 
setting from other healthcare settings in the 
community. Our results may not generalize to 
patients receiving insulin therapy or long-acting 
injectable antipsychotics as they were excluded 
from the study. Direct measurement of medication 
adherence was not possible due to the retrospective 
study design. CMGR was used as an indirect 
measurement of adherence which is calculated 
based on refill rates. The act of refilling a medication 
may not accurately reflect medication use and 
consumption, although this method is objective and 
has been correlated with other adherence 
behaviors.35-38 
Notwithstanding these limitations, our study has 
several strengths. This was conducted as an 
evaluation of normal clinical practice. Use of refill 
records to assess adherence did not interfere with 
normal processes and allowed for a naturalistic 
estimation of adherence. We included all patients 
who met criteria in the psychosis group and did not 
exclude patients for any reason (i.e. treatment 
resistance, history of medication nonadherence, 
comorbid substance abuse/dependence) thus 
reflecting a typical psychosis population. Other 
strengths of our study were inclusion of only those 
patients who received all of their medical and 
psychiatric care through the VA healthcare system, 
exclusion of all psychiatric diagnoses in the 
nonpsychiatric comparison group, and exclusive 
use of A1C values obtained in the primary care 
clinics which limited possible confounders. The use 
of widely accepted treatment guidelines for diabetes 
provides validity to the outcome measures selected 
for this study. Lastly, the 12-month assessment 
period is also a strength of our study. 
 
CONCLUSIONS 
Our study found no significant differences in 
antihyperglycemic medication adherence and 
glycemic control between outpatients with 
schizophrenia and related psychotic disorders and 
age-matched individuals without psychiatric illness 
receiving care in the VA healthcare system. 
Antihyperglycemic medication adherence and 
glycemic control was less than optimal for both 
groups. Adherence with antipsychotic medication 
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was found to be significantly associated with 
antihyperglycemic medication adherence. Additional 
research in this area should be conducted and 
include a larger sample size, replication in the VA 
healthcare system and non-VA sites in the 
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